Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Type 2 diabetes and heart failure: insights from the global DISCOVER study.
Arnold SV, Khunti K, Bonnet F, Charbonnel B, Chen H, Cid-Ruzafa J, Cooper A, Fenici P, Gomes MB, Hammar N, Ji L, Luporini-Saraiva G, Medina J, Nicolucci A, Ramirez L, Shestakova MV, Shimomura I, Surmont F, Tang F, Vora J, Watada H, Kosiborod M; DISCOVER investigators. Arnold SV, et al. Among authors: bonnet f. ESC Heart Fail. 2021 Apr;8(2):1711-1716. doi: 10.1002/ehf2.13235. Epub 2021 Feb 11. ESC Heart Fail. 2021. PMID: 33570253 Free PMC article.
Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program.
Ji L, Bonnet F, Charbonnel B, Gomes MB, Kosiborod M, Khunti K, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Shimomura I, Watada H, Fenici P, Hammar N, Hashigami K, Macaraeg G, Surmont F, Medina J. Ji L, et al. Among authors: bonnet f. J Diabetes Complications. 2017 Jul;31(7):1188-1196. doi: 10.1016/j.jdiacomp.2017.03.011. Epub 2017 Apr 5. J Diabetes Complications. 2017. PMID: 28499961 Free article.
What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER study.
Bonnet F, Chen H, Cooper A, Gomes MB, Ji L, Leigh P, Ramirez L, Shestakova MV, Shimomura I, Siddiqui A, Tang F, Vora J, Watada H, Khunti K. Bonnet F, et al. Diabetes Obes Metab. 2021 Oct;23(10):2336-2343. doi: 10.1111/dom.14476. Epub 2021 Aug 2. Diabetes Obes Metab. 2021. PMID: 34212481
Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER study.
Ji L, Bonnet F, Chen H, Cooper A, Hammar N, Leigh P, Luporini Saraiva G, Ramirez L, Medina J, Nicolucci A, Rathmann W, Shestakova MV, Surmont F, Tang F, Watada H; DISCOVER Investigators. Ji L, et al. Among authors: bonnet f. Diabetes Res Clin Pract. 2021 Aug;178:108947. doi: 10.1016/j.diabres.2021.108947. Epub 2021 Jul 10. Diabetes Res Clin Pract. 2021. PMID: 34252505
HbA1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study.
Bongaerts B, Kuss O, Bonnet F, Chen H, Cooper A, Fenici P, Gomes MB, Hammar N, Ji L, Khunti K, Medina J, Nicolucci A, Shestakova MV, Watada H, Rathmann W. Bongaerts B, et al. Among authors: bonnet f. Diabetes Obes Metab. 2023 Jul;25(7):1890-1899. doi: 10.1111/dom.15050. Epub 2023 Apr 5. Diabetes Obes Metab. 2023. PMID: 36906837
1,185 results